Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies
Investigative Ophthalmology & Visual Science · 2024-12-02 · 65 (14) · 1
DOI: 10.1167/iovs.65.14.1 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2024-12-02. Written by Melissa A Calton and 21 co-authors. Institution: 4D Molecular Therapeutics, Emeryville, California, United States. Major MEDLINE topics: Intravitreal Injections, Genetic Therapy, Dependovirus, Transgenes. Cited 24 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Intravitreal delivery of therapeutic transgenes to the retina via engineered viral vectors can provide sustained local concentrations of therapeutic proteins and thus potentially reduce the treatment burden and improve long-term vision outcomes for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy.
Methods
We performed directed evolution in nonhuman primates (NHP) to invent an adeno-associated viral (AAV) variant (R100) with the capacity to cross vitreoretinal barriers and transduce all regions and layers of the retina following intravitreal injection. We then engineered 4D-150, an R100-based genetic medicine carrying 2 therapeutic transgenes: a codon-optimized sequence encoding aflibercept, a recombinant protein that inhibits VEGF-A, VEGF-B, and PlGF, and a microRNA sequence that inhibits expression of VEGF-C. Transduction, transgene expression, and biological activity were characterized in human retinal cells in vitro and in NHPs.
Results
R100 demonstrated superior retinal cell transduction in vitro and in vivo compared to AAV2, a commonly used wild-type AAV serotype in retinal gene therapies. Transduction of human retinal pigment epithelial cells in vitro by 4D-150 resulted in dose-dependent transgene expression and corresponding reductions in VEGF-A and VEGF-C. Intravitreal administration of 4D-150 to NHPs was well tolerated and led to robust retinal expression of both transgenes. In a primate model of laser-induced choroidal neovascularization, 4D-150 completely prevented clinically relevant angiogenic lesions at all tested doses.
Conclusions
These findings support further development of 4D-150. Clinical trials are underway to establish the safety and efficacy of 4D-150 in individuals with wet AMD and DME.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- 4D Molecular Therapeutics, Emeryville, California, United States.
- Sierra Eye Associates, Reno, Nevada, United States.
- University of Nevada, Reno School of Medicine, Reno, Nevada, United States.
- University of California, Berkeley, California, United States.
Cite
APA
Calton, M. A., Croze, R. H., Burns, C., Beliakoff, G., Vazin, T., Szymanski, P., Schmitt, C., Klein, A., Leong, M., Quezada, M., Holt, J., Bolender, G., Barglow, K., Khoday, D., Mason, T., Delaria, K., Hassanipour, M., Kotterman, M., Khanani, A. M., …, & Kirn, D. (2024). Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies. Investigative Ophthalmology & Visual Science, 65(14), 1. https://doi.org/10.1167/iovs.65.14.1
Vancouver
Calton MA, Croze RH, Burns C, Beliakoff G, Vazin T, Szymanski P, et al. Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies. Investigative Ophthalmology & Visual Science. 2024;65(14):1. doi:10.1167/iovs.65.14.1
BibTeX
@article{Calton2024,
author = {Calton, Melissa A and Croze, Roxanne H and Burns, Christian and Beliakoff, Ghezal and Vazin, Tandis and Szymanski, Paul and Schmitt, Christopher and Klein, Austin and Leong, Meredith and Quezada, Melissa and Holt, Jenny and Bolender, Gabe and Barglow, Katherine and Khoday, Devi and Mason, Thomas and Delaria, Katherine and Hassanipour, Mohammad and Kotterman, Melissa and Khanani, Arshad M and Schaffer, David and Francis, Peter and Kirn, David},
title = {Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
volume = {65},
number = {14},
pages = {1},
doi = {10.1167/iovs.65.14.1}
}
EUVIMED